Centene Blows Past Q1 Estimates, Raises Guidance as Medicaid HBR Improves

What happened

Centene reported Q1 2026 adjusted diluted EPS of $3.37, roughly $0.50 ahead of expectations, and raised its full-year adjusted EPS guidance to above $3.40 from prior >$3.00. The improvement was driven by a Medicaid health benefit ratio (HBR) of 93.1%, which management attributed to tangible progress in managing medical costs and a moderate flu season. Despite the beat, the HBR remains elevated versus the low-90% levels needed for sustained margin recovery, and the ACA segment's performance was not separately highlighted. The company's earlier 2025 guidance withdrawal and goodwill impairment still weigh on credibility, though the strong quarter provides a near-term catalyst. Investors should view this as a positive step but await proof that HBR can trend sustainably toward 90% before assigning a higher multiple.

Implication

If Medicaid HBR can trend toward 90% over the next 2-3 quarters and ACA margins improve with 2026 repricing, the stock could re-rate toward our base case of $50 or bull case of $60. However, structural headwinds from BBBA cuts and ACA morbidity keep us cautious until multiple consecutive quarters of HBR improvement are visible.

Thesis delta

The Q1 beat and guidance raise improve near-term sentiment but do not yet confirm the durable HBR normalization needed for a full thesis upgrade. The Medicaid HBR of 93.1% is an improvement from prior quarters but remains above the 90% threshold that would trigger a bullish reassessment. We maintain our WAIT rating until we see clearer evidence that Medicaid and ACA margins are stabilizing in the low-90s or better.